- Home
- DOUG vs IPHA Comparison
DOUG vs IPHA Comparison
Compare DOUG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- IPHA
- Stock Information
- Founded
- DOUG 1911
- IPHA 1999
- Country
- DOUG United States
- IPHA France
- Employees
- DOUG N/A
- IPHA N/A
- Industry
- DOUG Building operators
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- IPHA Health Care
- Exchange
- DOUG Nasdaq
- IPHA Nasdaq
- Market Cap
- DOUG 142.2M
- IPHA 148.3M
- IPO Year
- DOUG N/A
- IPHA 2019
- Fundamental
- Price
- DOUG $1.58
- IPHA $1.79
- Analyst Decision
- DOUG
- IPHA Strong Buy
- Analyst Count
- DOUG 0
- IPHA 1
- Target Price
- DOUG N/A
- IPHA $11.50
- AVG Volume (30 Days)
- DOUG 1.0M
- IPHA 779.8K
- Earning Date
- DOUG 02-27-2025
- IPHA 09-12-2024
- Dividend Yield
- DOUG N/A
- IPHA N/A
- EPS Growth
- DOUG N/A
- IPHA N/A
- EPS
- DOUG N/A
- IPHA N/A
- Revenue
- DOUG $966,442,000.00
- IPHA $36,202,722.00
- Revenue This Year
- DOUG $5.28
- IPHA N/A
- Revenue Next Year
- DOUG $16.40
- IPHA $101.65
- P/E Ratio
- DOUG N/A
- IPHA N/A
- Revenue Growth
- DOUG 1.86
- IPHA N/A
- 52 Week Low
- DOUG $1.00
- IPHA $1.29
- 52 Week High
- DOUG $2.98
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- DOUG 38.30
- IPHA 45.92
- Support Level
- DOUG $1.49
- IPHA $1.64
- Resistance Level
- DOUG $1.84
- IPHA $1.87
- Average True Range (ATR)
- DOUG 0.12
- IPHA 0.12
- MACD
- DOUG 0.00
- IPHA -0.04
- Stochastic Oscillator
- DOUG 25.79
- IPHA 28.66
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.